TAVR Chugging Along at 5 Years in SURTAVI Trial
Researchers keeping an eye on the long-term outcomes of people undergoing transcatheter aortic valve replacement (TAVR) reported encouraging results in both clinical and economic terms, according to two reports from the Transcatheter Cardiovascular Therapeutics (TCT) meeting. The 5-year incidence of all-cause mortality or disabling stroke among people in the SURTAVI trial was no different between […]